

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Technology Appraisals and Guidance Information Services

### Static List Review (SLR)

<b>Title and TA publication number of static topic:</b>	TA124 Pemetrexed for the treatment of non-small-cell lung cancer
<b>Final decision:</b>	The guidance will remain on the 'static guidance list'

<b>1. Publication date:</b>	22 August 2007
<b>2. Date added to static list:</b>	March 2010
<b>3. Date the last searches were run:</b>	07 July 2009
<b>4. Current guidance:</b>	1.1 Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small-cell lung cancer. 1.2 People currently receiving pemetrexed should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
<b>5. Research recommendations from original guidance:</b>	None
<b>6. Current cost of technology/ technologies:</b>	Net price 100-mg vial = £160.00; 500-mg vial = £800.00

<b>7. Cost information from the TA (if available):</b>	“The acquisition cost of pemetrexed is £800 for a 500-mg vial (excluding VAT)”
<b>8. Alternative company(ies):</b>	Dr. Reddy's Laboratories (UK) Ltd Actavis UK Ltd
<b>9. Changes to the original indication:</b>	<p>Current SPC states that pemetrexed is indicated:</p> <p><i>“as monotherapy for the second-line treatment of patients with locally advanced or metastatic non – small cell lung cancer <u>other than predominantly squamous cell histology</u>”.</i></p> <p>This is the indication covered by TA124. Note that the underlined phrase, which has narrowed the licensed indication, has been added since the publication of TA124.</p>
<b>10. New relevant trials:</b>	None.
<b>11. Relevant NICE guidance (published or in progress):</b>	<p><a href="#">Lung cancer: diagnosis and management</a>. (2011) NICE clinical guideline CG121</p> <p><a href="#">Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin</a> (2016) NICE technology appraisal guidance 402</p> <p><a href="#">Pemetrexed for the maintenance treatment of non-small-cell lung cancer</a> (2010) NICE technology appraisal guidance 190</p> <p><a href="#">Pemetrexed for the first-line treatment of non-small-cell lung cancer</a> (2009) NICE technology appraisal guidance 181</p> <p><a href="#">Pemetrexed for the treatment of malignant pleural mesothelioma</a> (2008) NICE technology appraisal guidance 135</p>

[Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer](#) (2014) NICE technology appraisal guidance 310

[Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer](#) (2016) NICE technology appraisal guidance 395

[Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer](#) (2016) NICE technology appraisal guidance 422

[Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy](#) (2015) NICE technology appraisal guidance 374

[Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer](#) (2011) NICE technology appraisal guidance 227

[Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer](#) (2015) NICE technology appraisal guidance 347

[Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer](#) (2016) NICE technology appraisal guidance 416

[Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy](#) (2017) NICE technology appraisal guidance 428

[Lung cancer: diagnosis and management \(update\)](#) NICE clinical guideline Publication expected January 2019

[Atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy](#). NICE technology appraisal guidance [ID970] Publication expected October 2017

	<p><a href="#">Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer</a>. NICE technology appraisal guidance [ID1098] Publication expected April 2018</p> <p><a href="#">Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer</a>. NICE technology appraisal guidance [ID929] Publication expected TBC</p> <p><a href="#">Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy)</a>. NICE technology appraisal guidance [ID657] Publication expected TBC</p> <p><a href="#">Lung cancer (non-small-cell, non-squamous, metastatic, after treatment) - nivolumab</a>. NICE technology appraisal guidance [ID900] Publication expected TBC</p> <p><a href="#">Nivolumab for small-cell lung cancer after platinum-based chemotherapy</a>. NICE technology appraisal guidance [ID1126] Publication expected July 2018</p>
<p><b>12. Relevant safety issues:</b></p>	<p>Medicines and Healthcare products Regulatory Agency (2016) <a href="#">Pemetrexed 25mg/ml Concentrate for solution for Infusion: caution in use after particulates identified in a small number of vials (EL (16)A/09)</a></p>
<p><b>13. Any other additional relevant information or comments:</b></p>	<p>Pemetrexed is listed in the Cancer Drugs Fund but in relation to TA309 where it is given as maintenance treatment following induction therapy with pemetrexed and cisplatin.</p>
<p><b>14. Technical Lead comments and recommendation:</b></p>	<p>TA124 did not result in any recommendations for further research. While there are some new trials including pemetrexed since the original guidance was published, largely these involve pemetrexed as an option within a “standard of care” comparator. None could be considered relevant for this appraisal. It is therefore recommended that the appraisal remains on the static list.</p>

**SLR paper sign off:** Janet Robinson– Associate Director, Technology Appraisals

**Contributors to this paper:**

Technical Lead: Thomas Palmer

Information Specialist: Daniel Tuvey

Project Manager: Samantha Shannon

Date of IS searching: 30 May 2017 – 02 June 2017

## Appendix 1 – explanation of options

Options	Consequence	Selected – ‘Yes/No’
The guidance will remain on the ‘static guidance list’	The guidance will remain in place, in its current form, unless NICE becomes aware of substantive information which would make it reconsider. Searches are carried out every 5 years to check whether any of the Appraisals on the static list should be flagged for review.	Yes
The decision to review the guidance will be deferred to specify date or trial	NICE will consider whether a review is necessary at the specified date. NICE will actively monitor the evidence available to ascertain when a consideration of a review is more suitable.	No
A full consideration of a review will be carried out through the Review Proposal Process	There is evidence that could warrant a review of the guidance. NICE will schedule a consideration of a review, including a consultation with relevant consultees and commentators.	No
The guidance will be withdrawn	The guidance is no longer relevant and an update of the existing recommendations would not add value to the NHS. NICE will schedule a consideration of a review, including a consultation with relevant consultees and commentators.	No
The guidance should be updated in an on-going clinical guideline.	Responsibility for the updating the technology appraisal passes to the NICE Clinical Guidelines programme. Once	No

	<p>the guideline is published the technology appraisal will be withdrawn.</p> <p>NICE will schedule a consideration of a review, including a consultation with relevant consultees and commentators.</p>	
--	--	--